BBNX (Beta Bionics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BBNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Christy Jones | Director | Sell | — | — |
| 2026-09-18 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-09-17 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-09-17 | Mike Mensinger | Chief Product Officer | Sell | — | — |
| 2026-09-15 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-09-10 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-09-04 | Sean Saint | President & CEO | Sell | — | — |
| 2026-09-03 | Steven Jon Russell | Chief Medical Officer | Sell | — | — |
| 2026-09-03 | Sean Saint | President & CEO | Sell | — | — |
| 2026-09-03 | Stephen Feider | Chief Financial Officer | Sell | — | — |
| 2026-09-03 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-09-03 | Mike Mensinger | Chief Product Officer | Sell | — | — |
| 2026-07-02 | Stephen Feider | Chief Financial Officer | MIXED | — | — |
| 2026-06-25 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-06-25 | Christy Jones | Director | Sell | — | — |
| 2026-06-05 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-06-05 | Christy Jones | Director | Sell | — | — |
| 2026-06-03 | Sean Saint | President & CEO | Sell | — | — |
| 2026-06-03 | Stephen Feider | Chief Financial Officer | Sell | — | — |
| 2026-06-03 | Steven Jon Russell | Chief Medical Officer | Sell | — | — |
| 2026-06-03 | Mike Mensinger | Chief Product Officer | Sell | — | — |
| 2026-06-03 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-05-26 | Maria Palasis | Director | A | — | — |
| 2026-05-26 | Christy Jones | Director | MIXED | — | — |
| 2026-05-26 | GERARD J MICHEL | Director | A | — | — |
| 2026-05-26 | SEAN CARNEY | Director | A | — | — |
| 2026-05-26 | Danny L. Dearen | Director | A | — | — |
| 2026-05-26 | Adam Lezack | Director | MIXED | — | — |
| 2026-03-16 | Steven Jon Russell | Chief Medical Officer | Sell | — | — |
| 2026-03-16 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-03-13 | Stephen Feider | Chief Financial Officer | A | — | — |
| 2026-03-13 | Steven Jon Russell | Chief Medical Officer | A | — | — |
| 2026-03-13 | Sean Saint | President & CEO | A | — | — |
| 2026-03-13 | Mike Mensinger | Chief Product Officer | A | — | — |
| 2026-03-13 | Mark Hopman | Chief Commercial Officer | A | — | — |
| 2026-03-05 | Mark Hopman | Chief Commercial Officer | Sell | — | — |
| 2026-03-03 | Mike Mensinger | Chief Product Officer | MIXED | — | — |
| 2026-03-03 | Mark Hopman | Chief Commercial Officer | MIXED | — | — |
| 2026-03-03 | Stephen Feider | Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | Sean Saint | President & CEO | MIXED | — | — |
| 2026-03-03 | Steven Jon Russell | Chief Medical Officer | MIXED | — | — |
| 2026-01-14 | SEAN CARNEY | Director | A | — | — |
| 2026-01-14 | Christy Jones | Director | A | — | — |
| 2026-01-14 | Danny L. Dearen | Director | A | — | — |
| 2026-01-14 | GERARD J MICHEL | Director | A | — | — |
| 2026-01-14 | Maria Palasis | Director | A | — | — |
| 2026-01-14 | Adam Lezack | Director | A | — | — |
| 2026-01-07 | Mike Mensinger | Chief Product Officer | Sell | — | — |
| 2026-01-05 | Stephen Feider | Chief Financial Officer | MIXED | — | — |
| 2026-01-05 | Mike Mensinger | Chief Product Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,901,599 | — |
| — | President & CEO | 398,429 | — |
| — | Chief Product Officer | 177,390 | — |
| — | Chief Medical Officer | 169,628 | — |
| — | Chief Financial Officer | 159,378 | — |
| — | Chief Commercial Officer | 88,033 | — |
| — | Director | 33,509 | — |
| — | Director | 32,209 | — |
| — | Director | 32,209 | — |
| — | Director | 29,397 | — |
| — | Director | 27,399 | — |
| — | Director | 19,564 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBNX quote page; the site-wide leaderboard is on the insider transactions hub.